Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2

MT Newswires Live07-13

Voyager Therapeutics (VYGR) said Monday that it expects to begin its early Alzheimer's disease trial in adults in the second half of the year after the US Food and Drug Administration approved its investigational new drug application for VY1706 in June.

The company said that toxicology data from its trial in non-human primates showed VY1706 gene therapy was well tolerated and resulted in sustained tau protein reduction of up to 75% in key brain regions following a single intravenous dose over six months.

Voyager said that VY1706 demonstrated a favorable tolerability profile in the three- and six-month good laboratory practice toxicology study, with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, and peripheral organs up to the highest dose tested.

Shares of the company were up 3.2% in Monday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651811118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651811118","market":"fut","top_or_hot":-1,"title":"Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2","media":"MT Newswires Live","content":"<html><body><p> Voyager <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VYGR) said Monday that it expects to begin its early Alzheimer's disease trial in adults in the second half of the year after the US Food and Drug Administration approved its investigational new drug application for VY1706 in June.</p><p>The company said that toxicology data from its trial in non-human primates showed VY1706 gene therapy was well tolerated and resulted in sustained tau protein reduction of up to 75% in key brain regions following a single intravenous dose over six months.</p><p>Voyager said that VY1706 demonstrated a favorable tolerability profile in the three- and six-month good laboratory practice toxicology study, with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, and peripheral organs up to the highest dose tested.</p><p>Shares of the company were up 3.2% in Monday's premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVoyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-13 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Voyager <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VYGR) said Monday that it expects to begin its early Alzheimer's disease trial in adults in the second half of the year after the US Food and Drug Administration approved its investigational new drug application for VY1706 in June.</p><p>The company said that toxicology data from its trial in non-human primates showed VY1706 gene therapy was well tolerated and resulted in sustained tau protein reduction of up to 75% in key brain regions following a single intravenous dose over six months.</p><p>Voyager said that VY1706 demonstrated a favorable tolerability profile in the three- and six-month good laboratory practice toxicology study, with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, and peripheral organs up to the highest dose tested.</p><p>Shares of the company were up 3.2% in Monday's premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651811118","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651811118","pubTimestamp":1783946140,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Voyager Therapeutics  said Monday that it expects to begin its early Alzheimer's disease trial in adults in the second half of the year after the US Food and Drug Administration approved its investigational new drug application for VY1706 in June.The company said that toxicology data from its trial in non-human primates showed VY1706 gene therapy was well tolerated and resulted in sustained tau protein reduction of up to 75% in key brain regions following a single intravenous dose over six months.Voyager said that VY1706 demonstrated a favorable tolerability profile in the three- and six-month good laboratory practice toxicology study, with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, and peripheral organs up to the highest dose tested.Shares of the company were up 3.2% in Monday's premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VYGR":"Voyager Therapeutics Inc"},"translate_title":"Voyager Therapeutics 预计将在 H2 启动成人早期阿尔茨海默病研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VYGR":1.5},"content_text":"Voyager Therapeutics (VYGR) said Monday that it expects to begin its early Alzheimer's disease trial in adults in the second half of the year after the US Food and Drug Administration approved its investigational new drug application for VY1706 in June.The company said that toxicology data from its trial in non-human primates showed VY1706 gene therapy was well tolerated and resulted in sustained tau protein reduction of up to 75% in key brain regions following a single intravenous dose over six months.Voyager said that VY1706 demonstrated a favorable tolerability profile in the three- and six-month good laboratory practice toxicology study, with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, and peripheral organs up to the highest dose tested.Shares of the company were up 3.2% in Monday's premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651811118","isCrawlerRequest":true}